Latest From Nektar Therapeutics
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Nektar's IL-2 stimulating agonist NKTR-214 combines well with Bristol's Opdivo in Phase I PIVOT-02 study presented at SITC meeting in November.
Advisory committee asked to opine on whether there is substantial evidence of efficacy even though Phase III studies missed on three of four primary efficacy measures; Bayer argues that totality of the evidence demonstrates a meaningful benefit in reducing exacerbations in a heterogeneous patient population with the rare disease.
In the CheckMate 214 study in first-line renal cell carcinoma, Bristol's Opdivo/Yervoy combo beat Pfizer's Sutent on overall survival endpoint regardless of PD-L1 expression, supporting a bid for expanded labeling.
- Large Molecule
- Drug Delivery
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Immune Disorders
- Infectious & Viral Diseases
- Neurology, Nervous System
- Respiratory, Pulmonary
- Inhale Therapeutic Systems Inc.
- Nektar Therapeutics Inc.
- North America
- Parent & Subsidiaries
- Nektar Therapeutics
- Senior Management
Howard W Robin, Pres. & CEO
Gil M Labrucherie, SVP, CFO
John Nicholson, SVP, COO
Stephen K Doberstein, PhD, SVP, CSO
Ivan Gergel, MD, SVP, Drug Dev. & CMO
- Contact Info
Phone: (415) 482-5300
455 Mission Bay Blvd. S.
San Francisco, CA 94158
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.